Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

8.3%

5 terminated/withdrawn out of 60 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

28%

17 trials in Phase 3/4

Results Transparency

40%

16 of 40 completed trials have results

Key Signals

6 recruiting16 with results5 withdrawn

Enrollment Performance

Analytics

Phase 1

11(27.5%)

Phase 2

10(25.0%)

Phase 4

10(25.0%)

Phase 3

7(17.5%)

Early Phase 1

1(2.5%)

N/A

1(2.5%)

40Total

Phase 1(11)

Phase 2(10)

Phase 4(10)

Phase 3(7)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (60)

Showing 20 of 60 trials

NCT07357519Phase 1Recruiting

Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)

Role: lead

NCT03674255Enrolling By Invitation

Echocardiography: Value and Accuracy at REst and STress

Role: collaborator

NCT05394259Phase 1Recruiting

A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer

Role: collaborator

NCT07501650Phase 1Recruiting

Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer

Role: collaborator

NCT05160480Enrolling By Invitation

A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG

Role: collaborator

NCT03493516Active Not Recruiting

Prediction of ARrhythmic Events With Positron Emission Tomography II

Role: collaborator

NCT07335315Recruiting

Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors

Role: collaborator

NCT07084909Phase 2Withdrawn

Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC

Role: lead

NCT06074510Phase 4Active Not Recruiting

PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer

Role: lead

NCT06361810Phase 1Withdrawn

PSMA Therapy and Immunotherapy in Kidney Cancer

Role: collaborator

NCT06298916Phase 1Recruiting

64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

Role: lead

NCT04286100Active Not Recruiting

Contrast Specific Echocardiogram Versus Left Ventricular Opacification (LVO) Imaging Settings

Role: collaborator

NCT03297112Early Phase 1Completed

Contrast-Enhanced Subharmonic Ultrasound Imaging in Improving Characterization of Adnexal Masses in Patients Undergoing Surgery

Role: collaborator

NCT02764801Phase 3Completed

Contrast-enhanced Ultrasound Evaluation of Chemoembolization

Role: collaborator

NCT01490892Phase 4Completed

Quantitative Subharmonic Breast Imaging

Role: collaborator

NCT04557501Phase 3Active Not Recruiting

PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer

Role: collaborator

NCT05416385Recruiting

Carotid Intraplaque Neovascularization Combined With Stress Echo

Role: collaborator

NCT06033001Unknown

Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Role: lead

NCT03907657Phase 2Completed

Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau

Role: collaborator

NCT01005212Completed

Evaluation of Contrast-Enhanced Ultrasound to Detect Endoleaks After Endovascular Aortic Aneurysm Repair

Role: collaborator